.

Pharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Find generic sources and suppliers
  • Obtain formulation and manufacturing information

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 8,999,970

« Back to Dashboard

Which drugs does patent 8,999,970 protect, and when does it expire?

Patent 8,999,970 protects BELVIQ XR and BELVIQ and is included in two NDAs. There has been one Paragraph IV challenge on Belviq XR.

This patent has eighteen patent family members in thirteen countries.

Summary for Patent: 8,999,970

Title:Administration of an anti-obesity compound to individuals with renal impairment
Abstract: The present disclosure relates to methods for weight management in an individual in need thereof by determining the level of renal sufficiency of the individual and prescribing or administering a therapeutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual, provided that the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment. In addition, the disclosure relates to a method for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management by determining the level of renal sufficiency of the individual and selecting the individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof if the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment.
Inventor(s): Anderson; Christen M. (Encinitas, CA), Shanahan; William R. (Del Mar, CA)
Assignee: Arena Pharmaceuticals, Inc. (San Diego, CA)
Application Number:13/511,639
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Eisai Inc
BELVIQ XR
lorcaserin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208524-001Jul 15, 2016RXYesYes8,999,970► Subscribe METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
Eisai Inc
BELVIQ XR
lorcaserin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208524-001Jul 15, 2016RXYesYes8,999,970► Subscribe METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
Eisai Inc
BELVIQ XR
lorcaserin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208524-001Jul 15, 2016RXYesYes8,999,970► Subscribe METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
Eisai Inc
BELVIQ
lorcaserin hydrochloride
TABLET;ORAL022529-001Jun 27, 2012RXYesYes8,999,970► Subscribe METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
Eisai Inc
BELVIQ
lorcaserin hydrochloride
TABLET;ORAL022529-001Jun 27, 2012RXYesYes8,999,970► Subscribe METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,999,970

PCT Information
PCT FiledAugust 31, 2011PCT Application Number:PCT/US2011/049936
PCT Publication Date:March 08, 2012PCT Publication Number: WO2012/030939

International Patent Family for Patent: 8,999,970

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2808890► Subscribe
China103347523► Subscribe
Eurasian Patent Organization201390335► Subscribe
European Patent Office2611449► Subscribe
European Patent Office2939677► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc